Abstract
Cysteinyl leukotrienes are responsible for common symptoms in patients with rhinitis and asthma, including edema of the airways, contraction of smooth muscle, the presence of inflammatory cells, increased blood flow, edema of the mucosa and increased mucus secretion. This situation requires a therapeutic approach that concomitantly acts on the mediators responsible for the common symptoms. The alternative that showed the greatest reduction in symptoms was the combination of intranasal corticosteroids in combination with montelukast, followed by the combination of H1 antihistamines and montelukast.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
